We have previously shown that D2-Troglitazone (D2-TGZ) displayed anticancer effects on breast cancer cell lines grown in low serum conditions (1% fetal calf serum (FCS)). The present study was performed in order to characterize the effects of D2-TGZ in high serum containing medium and to determine if starvation could influence the response of breast cancer cells to this compound, keeping in mind the potential interest for breast cancer therapy. We observed that in high serum conditions (10% FCS), a 48 h treatment with D2-TGZ induced a decrease in cell numbers in MDA-MB-231 and MCF-7 breast cancer cell lines. The IC 50 values were higher than in low serum conditions. Furthermore, in contrast to our previous results obtained in 1% FCS conditions, we observed that in 10% FCS-containing medium, MCF-7 cells were more sensitive to D2-TGZ than MDA-MB-231 cells. D2-TGZ also induced endoplasmic reticulum (ER) stress mainly in MDA-MB-231 cells. Besides, in high serum conditions, D2-TGZ induced a G 0 /G 1 cell cycle arrest, an inhibition of BrdU incorporation and a reduced level of cyclin D1. We observed a limited cleavage of PARP and a limited proportion of cells in sub-G 1 phase. Thus, in high serum conditions, D2-TGZ displayed cytostatic effects rather than apoptosis as previously reported in 1% FCS-containing medium. Our results are in accordance with studies suggesting that serum starvation could potentiate the action of diverse anti-cancer agents.
Introduction
Breast cancer is the most frequent cancer in women worldwide and the second cause of cancer death in more developed regions of the world, after lung cancer. 1 Current treatments for breast cancer are surgery, radiotherapy, chemotherapy as well as endocrine therapy for hormone receptor-positive breast tumors and targeted therapies for human epidermal growth factor receptor 2 (HER2)-overexpressing tumors. 2 However, about 25% of estrogen receptor-positive breast cancer patients do not respond to the anti-estrogen tamoxifen and half of tamoxifen-treated patients develop a tamoxifen-resistant phenotype. 3 de novo and acquired resistance to the anti-HER2 monoclonal antibody trastuzumab have also been identified. 4 Besides, no targeted therapy is available for aggressive triplenegative breast cancer which is characterized by the absence of expression of estrogen, progesterone, and HER2 receptors. 5 These limitations in breast cancer therapy are strong arguments for the search for optimized therapeutic strategies and the development of new therapeutic agents. In this context, fasting cycles have been shown to retard the growth of tumors and to sensitize various cancer cell types to chemotherapy. 6 In regard to the development of alternative or complementary anticancer agents, thiazolidinediones (TZDs) are interesting compounds.
TZDs, including compounds like troglitazone (TGZ), ciglitazone (CGZ), pioglitazone (PGZ), and rosiglitazone (RGZ), are a class of synthetic agonists of peroxisome proliferator-activated receptor gamma (PPARg), initially used as insulin sensitizers for the treatment of type 2 diabetes. 7 In addition, TZDs have been investigated as anticancer drugs. The molecular mechanisms underlying the anticancer effects have been extensively studied, but are still not fully elucidated. Increasing data show that this activity is mainly related to PPARg-independent mechanisms. This has been demonstrated by experiments using PPARg-antagonists, transfection of dominant-negative PPARg isoforms, PPARg-targeted RNA interference as well as PPARginactive TZD derivatives like D2-TGZ or D2-CGZ. 8, 9 Such D2 analogs have a double bond adjoining the terminal thiazolidine-2,4-dione ring and they are devoid of PPARg activity. This attenuation of PPARg activity is explained by the structural rigidity induced by the double bond introduction surrounding the heterocycle system. 10, 11 In breast cancer cell lines, the number of viable cells was reduced after exposure to D2-TGZ. 12 Such a treatment induced a proteasome-dependent proteolysis of both cyclin D1 and estrogen receptor a in hormone-dependent breast cancer cell lines. [12] [13] [14] [15] Besides, D2-TGZ induced an early increase in intracellular calcium followed by the ERK-dependent expression of early growth response gene-1.
16 D2-TGZ also triggered endoplasmic reticulum (ER) stress followed by apoptosis in both MCF-7 and MDA-MB-231 breast cancer cells. Nevertheless, apoptosis did not seem to be a consequence of ER stress in MCF-7 cells. 17 Serum starvation is an experimental condition applied to limit undesirable effects on cell response due to the complex and non-standardized composition of serum. 18 It is also a routine procedure carried out to synchronize proliferating cells and to reduce basal cellular activity. 18 However, because of the reduction of the level of hormones and growth factors in the culture medium, serum starvation partially mimics the conditions of a metabolic stress. 18 It results in modulations of the cancer cell proteome and transcriptome, with almost 3,000 genes differentially expressed in MDA-MB-231 cells incubated either in 10% FBS (fetal bovine serum) or in 0.1% FBS-containing medium. 19, 20 Serum starvation triggers complex and unpredictable time-dependent and cell type-dependent effects, such as cell-cycle arrest and increased sensitivity to apoptosis. 18, 19, 21 In this context, culture conditions could influence the response of breast cancer cells to D2-TGZ. This compound was tested previously either in high serum conditions (5% or 10% fetal calf serum (FCS)-containing medium) 14, 22 or in a low serum environment (1% or 0% FCS-containing medium). 10, 12, 13, [15] [16] [17] Most data from our laboratory were obtained from breast cancer cell lines (MDA-MB-231 and MCF-7) cultured in 1% FCS-containing medium. In order to determine the impact of serum deprivation, we studied the effects of D2-TGZ on cells maintained in 10% FCS-containing medium. Our results show that in these conditions, D2-TGZ still induced a decrease in cell numbers but higher concentrations were required to obtain a drop of 50% compared to low serum conditions (1% FCS). Surprisingly, in 10% FCS-conditions, MCF-7 cells were more sensitive to D2-TGZ than MDA-MB-231 cells whereas the opposite was observed in 1% FCS conditions. Moreover, D2-TGZ induced cell cycle arrest rather than apoptosis, as previously reported in low serum conditions.
Results

D2-TGZ decreases less efficiently cell numbers in high serum conditions
At first, we investigated the effects of increasing concentrations of D2-TGZ on cell numbers and compared a treatment performed in 10% FCS-versus 1% FCS-containing medium. MDA-MB-231 and MCF-7 breast cancer cells were treated for 48 h and control cells received DMSO. Crystal violet staining assays revealed that higher concentrations of D2-TGZ were required to induce a 50% decrease in cell numbers in high serum conditions compared to low serum conditions (Fig. 1) . Indeed, in MDA-MB-231 cells, the IC 50 was 90.3 § 4.6 mM in 10% FCS-conditions vs. 7.1 § 0.5 mM in 1% FCS-conditions. Thus, D2-TGZ appeared 12.7-fold less efficient in high serum conditions. Similarly, in the hormone-dependent breast cancer cells MCF-7, the IC 50 was 57.0 § 4.4 mM in high serum conditions whereas it was 11.5 § 0.9 mM in low serum conditions. Thus, in this cell line, D2-TGZ appeared 4.95-fold less efficient in high serum conditions. Interestingly, MCF-7 cells were more sensitive to D2-TGZ than MDA-MB-231 cells when the treatment was performed in 10% FCS-conditions whereas the opposite was observed in 1% FCS-conditions. Figure 1 . D2-TGZ decreases less efficiently cell numbers in high serum conditions. MDA-MB-231 and MCF-7 cells were treated for 48 h with increasing concentrations of D2-TGZ in 10% or 1% FCS-containing medium. Control cells were treated with DMSO. Cell numbers were assessed by a crystal violet staining assay and the IC 50 were determined. Results are depicted as mean § s.e.m. of three independent counts performed in triplicate. Significant differences with control cells are indicated ( Ã P < 0.05;
D2-TGZ inhibits less efficiently cell proliferation in high serum conditions Then, it was interesting to determine what kind of mechanism was involved in the decrease in cell numbers observed when D2-TGZ was applied in 10% FCS-containing medium. So, we used a BrdU incorporation assay to study cell proliferation (Fig. 2) . MDA-MB-231 and MCF-7 cells were treated for 48 h with increasing concentrations of D2-TGZ in high (10% FCS-containing medium) or low serum (1% FCS-containing medium) conditions. Control cells were treated with DMSO.
In MDA-MB-231 cells, D2-TGZ treatment inhibited BrdU incorporation with an IC 50 of 70.6 § 0.8 mM in 10% FCSconditions versus 3.8 § 0.6 mM in 1% FCS-conditions. Thus, in this cell line, D2-TGZ was 18.6-fold less potent to inhibit cell proliferation in high serum conditions. In MCF-7 cells, BrdU incorporation was inhibited by D2-TGZ treatment with an IC 50 of 58.6 § 2.6 mM in 10% FCS-conditions vs. 10.4 § 0.7 mM in 1% FCS-conditions. Thus, in this cell line, D2-TGZ was 5.6-fold less efficient to inhibit BrdU incorporation in high serum conditions. Besides, as described above for cell number analysis, when D2-TGZ was applied in 10% FCS-containing medium, MCF-7 was the most sensitive of the 2 cell lines whereas MDA-MB-231 was the most sensitive one in low serum conditions.
D2-TGZ triggers ER stress in high serum conditions
We have shown recently that D2-TGZ triggered ER stress in breast cancer cell lines (MDA-MB-231 and MCF-7) when applied in low serum conditions. 17 In order to investigate if D2-TGZ still induced ER stress in 10% FCS-conditions, cells were treated with D2-TGZ during a time course in 10% FCS-containing medium and several players of the unfolded protein response (UPR) pathway that is activated in case of ER stress were studied. We focused on the pancreatic endoplasmic reticulum kinase-like endoplasmic reticulum kinase (PERK) and the eukaryotic initiation factor 2a (eIF2a) that are responsible for a slowing down of protein translation and the inositol requiring enzyme 1 (IRE1)-dependent X-box-binding protein-1 (XBP-1) mRNA cleavage that is required for the synthesis of a highly active transcription factor responsible for the expression of the immunoglobulin heavy chain binding protein (BiP), a chaperone that binds to unfolded proteins.
23 D2-TGZ was used at 75 mM and 60 mM for MDA-MB-231 and MCF-7 cells, respectively. These values were just above the IC 50 values determined in BrdU incorporation assays. Control cells received DMSO.
In MDA-MB-231 cells, western blot analysis revealed an enhanced phosphorylation of PERK in case of exposure to D2-TGZ (Fig. 3A) . Indeed, PERK displayed an electrophoretic mobility shift which was detected in samples collected 6 h after D2-TGZ treatment and was total after 72 h. The activation of PERK was confirmed by the phosphorylation of eIF2a on Ser51. Indeed, a 4.2-fold increase in phosphorylation at this site was detected 6 h after D2-TGZ treatment, and a 28.2-fold increase after 48 h. The phosphorylated form was still present after 72h. RT-PCR analyses also revealed a cleavage of XBP-1 mRNA in MDA-MB-231 cells exposed to D2-TGZ (Fig. 3B) . Indeed both spliced and unspliced XBP-1 mRNA were detected 6 h after exposure to D2-TGZ and only spliced XBP-1 mRNA were present after 72 h of treatment. Regarding the chaperone BiP, we observed a 6.6-fold induction of its expression after 24 h of treatment with D2-TGZ and this induction was still Figure 2 . D2-TGZ inhibits less efficiently cell proliferation in high serum conditions. MDA-MB-231 and MCF-7 cells were treated for 48 h with increasing concentrations of D2-TGZ in high serum (10%) or in low serum (1%) conditions. Control cells were treated with DMSO. Cell proliferation was evaluated by a BrdU incorporation assay using the BrdU Cell Proliferation Assay Kit and the IC 50 were determined. Results are depicted as mean § s.e.m. of three independent experiments performed in triplicate.
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present after 72 h (Fig. 3A) . We did not detect any of these events in control cells treated with DMSO.
We also studied the effects of D2-TGZ on ER stress in MCF-7 cells in 10% FCS-conditions. D2-TGZ did not induce the phosphorylation of PERK since no shift could be detected on protein gel blot whatever the time of treatment (Fig. 3A) . We did not observe an increased phosphorylation of eIF2a either (Fig. 3A) . Furthermore, no splicing of XBP-1 mRNA was detected during the time course of D2-TGZ treatment (Fig. 3B ). Nevertheless, we observed an increase of BiP expression in case of D2-TGZ treatment: it reached 1.7-fold at 6 h and 7.1-fold after 24 h. It was maintained after 72 h (Fig. 3A) . Control cells did not show any increase of BiP expression.
When UPR is not sufficient to restore ER functions, apoptosis can be initiated. The transcription factor CEBP homologous protein (CHOP) can mediate this event.
24 MDA-MB-231 and MCF-7 cells were treated for 24 and 48 h with D2-TGZ (75 mM and 60 mM, respectively) in 10% FCS-containing medium and control cells received DMSO (Fig. 4) . In both cell lines, immunolocalisation studies revealed a nuclear staining after 24 h of D2-TGZ treatment which was stronger after 48 h. No nuclear staining was observed in control cells at 24 and 48 h.
D2-TGZ induces cell cycle arrest rather than apoptosis in high serum conditions
We showed recently that D2-TGZ triggers apoptosis in both MDA-MB-231 and MCF-7 cells when grown in 1% FCS-containing medium. 17 In order to determine if D2-TGZ also induced apoptosis in 10% FCS-conditions, both cell lines were treated for 72 h with D2-TGZ (75 mM for MDA-MB-231 cells and 60 mM for MCF-7 cells) in 10% FCS-containing medium. Control cells received DMSO. We also performed a 48 h treatment with the apoptosis inducing agent staurosporine (0.5 mM) as a positive control. First, we studied by western blot the cleavage of the poly (ADP-ribose) polymerase (PARP) that is a caspase substrate (Fig. 5A ). In MDA-MB-231 cells exposed to DMSO, no cleaved PARP was detected at 48 h, whereas a residual level of cleaved PARP was present after 72 h. In cells exposed to staurosporine for 48 h, a high level of cleaved PARP was observed. In cells exposed to D2-TGZ, we did not observe a cleavage of PARP even after 72 h of treatment. In MCF-7 cells, we did not observe cleaved PARP in control cells exposed to DMSO. In cells exposed to staurosporine for 48 h, a high level of cleaved PARP was observed. The anti-cleaved PARP antibody revealed a faint band in cells treated for 72 h with D2-TGZ.
Besides, we also determined the percentage of cells in sub-G 1 phase, corresponding to the apoptotic cells, by flow cytometry (Fig. 5B) . In MDA-MB-231 cells, 1.2 § 0.1% and 1.1 § 0.1% of control cells were detected in sub-G 1 phase at 48 and 72 h respectively. In cells exposed to D2-TGZ, there were 3.8 § 0.4 and 4.8 § 0.7% of cells in sub-G 1 phase after 48 and 72 h respectively, suggesting that D2-TGZ induced a slight increase of cells in sub-G 1 phase. In MCF-7 cells, 3.4 § 0.6% of control cells were in sub-G 1 phase at 48 h and this percentage did not vary after 72 h (3.0 § 0.9%). In cells treated with D2-TGZ, we observed 4.7 § 0.4% of cells in sub-G 1 phase after 48 h and 9.5 § 1.9% of cells after 72 h, suggesting that D2-TGZ Then, we hypothesized that when applied in high serum containing medium, D2-TGZ could induce a cell cycle arrest instead of triggering apoptosis. Hence, we determined the percentage of cells in each phase of the cell cycle by flow cytometry ( In addition to this flow cytometry analysis, we studied cyclin D1 that is a major player of the G 1 /S transition of the cell cycle. Western blot analysis showed that in MDA-MB-231 cells, cyclin D1 was detected in control cells but no signal was observed in cells treated with D2-TGZ for 72 h (Fig. 5C) . In MCF-7 cells, the level of cyclin D1 was decreased in D2-TGZtreated cells after 72 h (3.2-fold), but a residual level of protein was still detected. Thus, we observed a decrease of cyclin D1 expression in both cell lines after 72 h of treatment with D2-TGZ, in agreement with a cell cycle blockage in G 0 /G 1 phase.
Discussion
The present study was performed in order to characterize the effects of D2-TGZ in high serum containing medium and to determine if serum starvation could influence the response of cancer cells to potential therapeutic agents.
In our previous studies where D2-TGZ treatment was performed in 1% FCS-conditions, an ATP-based cell viability assay indicated that after 24 h of treatment, the IC 50 values were 16.6 mM for MDA-MB-231 cells and 29.7 mM for MCF-7 cells. 12 In the current study, the IC 50 values obtained by a crystal violet staining assay were 7.1 mM for MDA-MB-231 cells and 11.5 mM for MCF-7 cells after 48 h of treatment in similar low serum conditions (1%). It was not surprising that these values were lower since treatment duration was longer (48 h). Nevertheless, the sensitivity of both cell lines to D2-TGZ was approximately the same: MCF-7 cells were 1.79-fold less sensitive than MDA-MB-231 cells after 24 h and 1.62-fold after 48 h. Thus, there was a consistency between our present and previous results although different methods were used to determine IC 50 values.
Our comparative analysis also revealed a difference of sensitivity of MCF-7 and MDA-MB-231 cells to D2-TGZ depending on the percentage of FCS in culture medium. Interestingly, similar results were obtained with genistein. 25 Indeed, MCF-7 cells were more sensitive than MDA-MB-231 cells when 10 mM of genistein was applied in 10% FCS conditions whereas the opposite situation was observed in 2% FCS conditions. This differential response could be the consequence of the difference of sensitivity of the breast cancer cell lines to growth factors, highly present in FBS. Indeed, triple-negative cells are more responsive to a large range of growth factors than other subtypes, likely modulating their sensitivity to antiproliferative compounds. 26 The higher amount of growth factors present in high serum conditions could also explain that higher concentrations of D2-TGZ were required to induce a decrease in cell numbers. These results are in agreement with the study of Yang et al. showing that 10 mM of D2-TGZ were sufficient to significantly reduce LNCaP prostate cancer cells viability after 24 h of treatment in serum-free conditions whereas no considerable effect was detected with up to 50 mM of D2-TGZ in 10% FCS conditions. 11 Thus, the reduced sensitivity of cells to D2-TGZ in high serum conditions is not restricted to breast cancer cells. Besides, a study reported that troglitazone, the parent molecule of D2-TGZ, activated the ERK pathway and induced p21 Cip/WAF1 in the colorectal cancer cell lines HCT15 and HT29 with a dose of 200 mM in 10% FBS-conditions, whereas 20 mM of TGZ were enough to induce these effects in 1% FBSconditions. 27 Moreover, another study showed that a 7-fold increase in the IC 50 of the antitumor drug Sorafenib (BAY 43-9006, Nexavar) was necessary to inhibit ERK 1/2 phosphorylation in MDA-MB-231 cells in presence of serum, compared to a low protein containing medium (0.1% Bovine Serum Albumin and 0% FCS-containing medium). 28 So, serum starvation enhances the action of D2-TGZ and of other antiproliferative compounds in cancer cells.
We further studied the effects of D2-TGZ on ER stress. In our previous studies performed in low serum conditions, we showed that D2-TGZ treatment was followed early by the activation of PERK/eIF2a and IRE1/XBP-1 axes of the UPR in both MDA-MB-231 and MCF-7 cells. 17 We also observed in both cell lines a later increase in the expression of the chaperone BiP as well as the induction of CHOP, the latter being translocated in the nucleus. In this context, we showed that ER stress was not causative of apoptosis. 17 In the present work, the same responses were observed in MDA-MB-231 cells that were treated with D2-TGZ in high serum conditions. Since no apoptosis was detected, these results reinforced our conclusion on the absence of link between D2-TGZ-induced ER stress and apoptosis. In MCF-7 cells, when D2-TGZ treatment was performed in 10% FCS-conditions, we observed neither PERK and eIF2a phosphorylation nor the splicing of XBP-1. This suggests that MDA-MB-231 cells are more prone to activate ER stress pathways than MCF-7 cells. This is in agreement with our previous studies since in low serum conditions, starvation by itself (in absence of D2-TGZ treatment) triggered PERK-eIF2a axis activation in MDA-MB-231 cells. Moreover, we observed a lower amount of spliced XBP-1 mRNA in MCF-7 cells than in MDA-MB-231 cells after D2-TGZ exposure. 17 Similarly, TZD18, a PPARa/g dual agonist, and the indole-3-carbinol cyclic tetrameric derivative CTet were reported to induce a more extended splicing of XBP-1 mRNA in MDA-MB-231 cells than in MCF-7 cells. 29, 30 Despite a higher susceptibility of MDA-MB-231 cells to ER stress activation than MCF-7 cells, we observed a later increase of BiP expression and CHOP induction in both cell lines in response to D2-TGZ in high serum conditions. Since PERK/eIF2a and IRE1/XBP-1 pathways were not activated in MCF-7 cells in 10% FCS conditions, a transcription factor like ATF6 could be involved in the stimulation of BiP and CHOP expressions in these cells. 31 We then investigated apoptosis since it was triggered by D2-TGZ in low serum conditions. 17 In 10% FCS-conditions, D2-TGZ induced only a minor apoptotic response in both cell lines, as suggested by the limited cleavage of PARP and the slight increase of cells in sub-G 1 phase. This result was consistent with the effects of other compounds like the natural compound guttiferone F which was shown to trigger apoptosis of LNCaP and PC3 prostate cancer cells in serum-free conditions, whereas no apoptosis was detected in 10% FBS-conditions. 32 In small cell lung cancer cells, the tyrosine kinase inhibitor STI571 did not induce apoptosis in 10% FCS-conditions while this event appeared in a serum-free medium supplemented with stem cell factor. 33 Nevertheless, apoptosis in high serum conditions could be induced by elevated doses of compounds as suggested for TGZ and resveratrol. 34, 35 Indeed, 10 mM of troglitazone was enough to induce DNA fragmentation in 0.1% FCS-conditions, whereas more than 100 mM of TGZ was required in a 10% FCS-containing medium. 34 For resveratrol, 150 mM of compound, instead of 50 mM, were necessary to trigger apoptosis in MCF-7 cells. 35 Thus, we cannot exclude that, in our conditions, doses of D2-TGZ above 100 mM would activate an apoptotic response.
An explanation for the differential effect of D2-TGZ on apoptosis between low and high serum conditions could arise from a cellular stress triggered by serum starvation. Several data demonstrated that serum deprivation modifies cell physiology by mimicking the conditions of an "environmental stress," resulting in the initiation of different cellular and molecular responses according to the cell type and the duration of starvation. 18 We previously reported that MDA-MB-231 cells grown in low serum conditions displayed partial ER stress with phosphorylation of PERK and eIF2a. 17 Similar culture conditions induced an increase in the production of reactive oxygen species, leading to the initiation of apoptosis of 5123tc rat hepatoma cells. 36 This type of cell death was also detected in HN9.10e hippocampal neuroblasts incubated in 0.2% FBS-containing medium. 37 Furthermore, Levin et al. reported in a large study that culture of various human adenocarcinoma cells (breast, pancreatic, colon and ovarian cells) in low serum condition (0.5% FBS), compared to the well-fed condition of growth (10% FBS), led to an augmentation of proteins and phosphoproteins implicated in apoptotic pathways. They reported in particular an increase in p53 and decreases in Bad (Ser155), Bcl-xL and cIAP-1 proteins. 19 Thus, serum starvation could sensitize cancer cells to apoptosis. Nevertheless, some studies also describe the resistance of cancer cells to cell death induced by nutrient/serum deprived conditions. For instance, some members of the transcriptional regulator interacting with the PHD-bromodomain (TRIP-Br) family were reported to be involved in such phenomenon. 38, 39 One might suggest that D2-TGZ could disturb the molecular mechanisms responsible for this protection against apoptosis.
Rather than apoptosis, we observed that D2-TGZ induced in both breast cancer cell lines a cell cycle blockage in G 0 /G 1 phase, with a concomitant decrease of the number of cells in S phase, which is consistent with the inhibition of BrdU incorporation observed after 48 h of treatment. Similarly, in MDA-MB-435 breast carcinoma cells, 50 mM of TGZ induced the cell cycle arrest in G 0 /G 1 phase after 64 h of treatment. 40 This G 0 / G 1 arrest was in agreement with the reduced level of cyclin D1 since this protein is required for driving the G 1 /S transition. 12, 41 This is probably the result of proteolysis of cyclin D1 through an ubiquitin-dependent mechanism implicating the F-box protein b-transducin repeat-containing protein (b-TrCP) which has been described in several studies. 42, 43 To conclude, the present study shows that in high serum conditions (10% FCS), D2-TGZ still displayed anticancer effects on MDA-MB-231 and MCF-7 breast cancer cells. MCF-7 cells were more sensitive to D2-TGZ than MDA-MB-231 cells in high serum conditions, whereas the opposite situation was observed in low serum conditions. Besides, D2-TGZ induced cytostatic effects in high serum conditions whereas apoptosis occurred in low serum conditions. This is in accordance with studies suggesting that serum starvation, as well as short-term starvation (glucose and serum restriction), enhanced the action of diverse chemotherapeutic agents in various cancer cells. 6, 44 mTOR pathway could be involved in this process since it is inhibited in low serum conditions and mTOR inhibitors like rapamycin sensitize cancer cells to anticancer drugs. 45, 46 Then, it could be on purpose to test the potentiating effect of the co-treatment rapamycin/D2-TGZ on breast cancer cells. Moreover, the starvation-based method was named the differential stress resistance since it potentiated the action of the chemotherapeutic agent toward cancer cells while being less deleterious for normal cells. 47 This condition could be taken into account for in vivo experiments in which D2-TGZ or its derivatives will be tested.
Materials and methods
Cell lines and reagents
MDA-MB-231 and MCF-7 human breast cancer cell lines were obtained from American Type Culture Collection. Both cell lines were grown at 37 C under 5% CO 2 in Dulbecco's Modified Eagle Medium (DMEM, Thermo Fisher Scientific, 41965-039) for MCF-7 and Roswell Park Memorial Institute (RPMI) 1640 medium (Thermo Fisher Scientific, 21875-034) for MDA-MB-231. These phenol red containing media were supplemented with 2 mM L-glutamine (Sigma-Aldrich) and fetal calf serum (FCS, Sigma-Aldrich).
D2-TGZ was synthetized according to experimental procedures described previously. 48 The identity and purity of this compound were verified by proton nuclear magnetic resonance and elemental analysis. D2-TGZ was dissolved in Dimethyl sulfoxide (DMSO). DMSO and staurosporine (STS) were obtained from Sigma-Aldrich. 
Crystal violet staining assay
At the end of the treatment, cells were washed with phosphatebuffered saline (PBS). Cells were then fixed and stained for 20 min with 0.2% crystal violet (Sigma-Aldrich, C6158) in 2% ethanol. This staining solution was filtered prior to use with a syringe-driven filter unit (0.22 mm pore size, Millipore, SLGP033RS) to eliminate dye precipitates. Cells were then washed with distilled water to remove excess dye. The plates were dried and the dye was dissolved in 10% acetic acid. Cell number was determined by absorbance at 595 nm with a VICTOR TM X3 multilabel plate reader (PerkinElmer, Courtaboeuf, France). In each condition, the concentration leading to a decrease of 50% of the cell number (IC 50 ) was determined.
Bromodeoxyuridine (BrdU) incorporation assay
Cell proliferation was measured using the BrdU Cell Proliferation Assay Kit (Millipore, 2752) according to the manufacturer's instructions. Twenty mL of BrdU label solution were added to each well 24 h prior to the end of the treatment. The amount of BrdU incorporated in the cells was measured by absorbance at 450 nm with a VICTOR TM X3 multilabel plate reader (PerkinElmer). In each condition, the concentration leading to a decrease of 50% of the BrdU incorporation (IC 50 ) was determined.
Western immunoblotting
At the end of the treatment, adherent cells were scraped in the culture medium containing the non-adherent cells and all cells were collected by centrifugation at 1000 rpm for 5 min at 4 C. The pellet was rinsed with PBS and resuspended in 20 mL of lysis buffer containing: 10 mM Tris-HCl pH 7.4, 5 mM EDTA, 1% Triton X-100, protease inhibitors (cOmplete TM Mini, Roche, Sigma-Aldrich, 11836153001) and phosphatase inhibitors (Phosphatase Inhibitor Cocktail Set V, Calbiochem, Millipore, 524629). The cell lysate was clarified by centrifugation at 1000 rpm for 10 min at 4 C. Protein concentration was determined by the Bradford method (Bio-Rad Protein Assay, BioRad Laboratories, 5000006).
50 mg of total proteins were mixed with 5£ Laemmli buffer, heated (95 C, 5 min) and subjected to 12% SDS-PAGE (7% in case of PERK analysis). After electrophoresis, proteins were transferred on a nitrocellulose membrane (Amersham, GE Healthcare Life science, 10600003). The homogeneity of loaded amounts and transfer efficiency were checked by Ponceau S staining of nitrocellulose membranes. Membranes were incubated in TNT buffer (50 mM Tris-HCl, 150 mM NaCl, 0.1% Tween 20) with 5% non-fat powder milk for 2 h at room temperature to reduce nonspecific binding of antibodies. They were then incubated with the primary antibodies diluted in the blocking solution overnight at 4 C. The rabbit monoclonal antibodies anti-BiP (United States Biological, Euromedex, B1770) and anti-PERK (Cell Signaling Technology, Ozyme, clone C33E10, 3192), the rabbit polyclonal antibodies antiphospho (Ser51) eIF2a (Signalway Antibody, Euromedex, 11279), anti-a-Tubulin (GeneTex, Euromedex, GTX102079) and anti-cyclin D1 (GeneTex, GTX108624), the mouse monoclonal antibody anti-cleaved PARP (Asp214) (BD Pharmingen~, BD Biosciences, 552596) and the goat polyclonal antibody antiActin (Santa Cruz Biotechnology, sc-1615) were diluted at 1:1000. Next, membranes were washed 3 times with TNT and incubated for 1 h with appropriate peroxidase-linked secondary antibodies (Santa Cruz Biotechnology, sc-2004, sc-2005, sc-2020) at room temperature. After three washings with TNT, membranes were developed with the Clarity~Western ECL Substrate detection reagent (Bio-Rad Laboratories, 170-5061) using chemiluminescence and observed with a ChemiDoc~XRS imaging system (Bio-Rad Laboratories, Marne-la-Coquette, France). Western blots were then subjected to quantification using Quantity One software (Bio-Rad Laboratories). The ratio between the intensity of the band of interest and actin or a-tubulin was calculated to obtain the level of induction of the protein of interest after treatment. For PERK electrophoretic mobility shift detection, blots were developed on X-ray films (Amersham, GE Healthcare Life science, 28-9888-21).
Semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR)
At the end of the treatment, total RNA was extracted using C. The number of cycles was chosen to realize the analysis in the linear phase of the PCR reaction. 25 mL of the PCR product were mixed with loading buffer (5 mL) and 15 mL of the mixture were submitted to electrophoresis in a 1% agarose gel (3% in case of XBP-1 analysis) at 100 V for 30 min at room temperature. The gel was stained with ethidium bromide, viewed and photographed on a UV-transilluminator (GelDoc 2000, Bio-Rad Laboratories).
Immunocytochemistry
At the end of the treatment, cells were fixed in PBS containing 4% paraformaldehyde (Sigma-Aldrich) for 15 min at room temperature. After three washings with PBS, cells were permeabilized for 10 min in PBS containing 0.5% Triton X-100, washed 3 times with PBS and incubated for 30 min in a blocking solution (0.1% Triton X-100, 4% bovine serum albumin in PBS buffer) to reduce nonspecific binding of antibodies. Preparations were then incubated with the mouse monoclonal antibody anti-CHOP (SC-7351, Santa Cruz Biotechnology) diluted at 1:100 in the blocking solution overnight at 4 C. They were then washed 3 times in PBS/0.1% Triton X-100 and exposed for 1 h in the dark to Alexa Fluor Ò 555 goat anti-mouse IgG antibody (Invitrogen, A-21422) diluted at 1:1000 in PBS/0.1% Triton X-100. Finally, cells were rinsed 3 times with PBS and counterstained with Hoechst dye (Sigma-Aldrich, 17535-AAT) to visualize nuclei. Fluorescence labeling was observed under an Eclipse 80i microscope (Nikon, Champigny-sur-Marne, France). Images were collected using LuciaG 4.81 software (Nikon).
Cell cycle analysis
At the end of the treatment, culture medium containing the non-adherent cells was collected. Adherent cells were washed with PBS, trypsined (0.05% trypsin-EDTA in PBS buffer, Thermo Fisher Scientific, 15400054) and resuspended in a medium containing 10% FCS. Non-adherent cells and trypsined cells were pooled and counted using a TC20 TM Automated Cell Counter (Bio-Rad Laboratories). 1 £ 10 6 cells were centrifuged at 500 g for 5 min at room temperature and the pellet was rinsed with PBS. Cells were then resuspended in 600 mL of PBS and 1,400 mL of cold absolute ethanol were added dropwise while vortexing the suspension to permeabilize and fix the cells efficiently. 5 £ 10 5 cells were then centrifugated at 800 g for 10 min at room temperature. The pellet was resuspended in 500 mL of DNA staining solution containing 200 mg of RNAse A (Invitrogen, 12091021) and 2 mg of propidium iodide (PI) (Life Technologies~, Thermo Fisher Scientific, P3566). Samples were incubated for 15 min in the dark at room temperature. Finally, cellular DNA content was determined with a BD FACSCalibur~flow cytometer (BD Biosciences, Le Pont de Claix, France) using CellQuest TM Pro software (BD Biosciences). 20,000 events were analyzed and the percentage of cells in each phase of the cell cycle was determined.
Statistical analysis
The results of crystal violet staining assays, BrdU incorporation assays and those of cell cycle analysis were depicted as mean § standard error of the mean (s.e.m) of at least 3 independent experiments. Statistical tests were performed using GraphPad InStat software. Data from BrdU incorporation and crystal violet staining assays were analyzed performing one-way analysis of variance (ANOVA) followed by the Bonferroni post test for multiple comparisons. Differences in which P-value was less than 0.05, 0.01 or 0.001 were statistically significant, very significant or extremely significant respectively. The results of cell cycle analysis were examined using a 2-tailed paired t test. Differences in which P-value was less than 0.05 were statistically significant. 
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